

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 May 2019 (02.05.2019)



(10) International Publication Number
WO 2019/084383 A1

(51) International Patent Classification:

C07D 451/14 (2006.01) C07D 403/12 (2006.01)
C07D 451/04 (2006.01) A61K 31/519 (2006.01)

(21) International Application Number:

PCT/US2018/057682

(22) International Filing Date:

26 October 2018 (26.10.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/577,852 27 October 2017 (27.10.2017) US

(71) Applicant: **THERAVANCE BIOPHARMA R&D IP, LLC** [US/US]; 901 Gateway Boulevard, South San Francisco, California 94080 (US).

(72) Inventors: **KOZAK, Jennifer**; 771 Prairie Creek Drive, Pacifica, California 94044 (US). **HUDSON, Ryan**; 1454 Walbrook Drive, San Jose, California 95129 (US). **BRANDT, Gary E.L.**; 2160 Buena Vista Avenue, Alameda, California 94501 (US). **MCKINNELL, Robert Murray**; 321 Poplar Avenue, Millbrae, California 94030 (US). **DABROS, Marta**; 888 Foster City Boulevard, Apt. Q2, Foster City, California 94404 (US). **NZEREM, Jerry**; 29 Woods Circle, South San Francisco, California 94080 (US).

(74) Agent: **HAGENAH, Jeffrey A.** et al.; Theravance Biopharma US, INC., 901 Gateway Boulevard, South San Francisco, California 94080 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: PYRIMIDINE COMPOUND AS JAK KINASE INHIBITOR



(57) Abstract: The invention provides a compound of formula (I): (Formula (I)) or a pharmaceutically-acceptable salt thereof, that is an inhibitor of JAK kinases. The invention also provides pharmaceutical compositions comprising such compound, a crystalline form, methods of using such compound to treat inflammatory skin diseases and other diseases, and processes and intermediates useful for preparing such compound.



WO 2019/084383 A1